Patents by Inventor Elisabeth Letellier

Elisabeth Letellier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for cancer diagnosis, prediction or staging
    Patent number: 11834717
    Abstract: The present invention relates to a method for predicting clinical outcome for a subject diagnosed with colorectal cancer, skin cancer, head and neck cancer or lung cancer. It also relates to a method for predicting whether a subject has a predisposition to develop such cancers as well as to a method for aiding the staging of such cancers in a subject. The methods of the present invention apply to the biomarkers MYO5B and/or RAB8A and optionally in addition to RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC and/or RhoA.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 5, 2023
    Assignee: Universite du Luxembourg
    Inventors: Elisabeth Letellier, Martine Schmitz, Aurelien Ginolhac, Serge Haan
  • NOVEL BIOMARKERS FOR CANCER DIAGNOSIS, PREDICTION OR STAGING
    Publication number: 20200362417
    Abstract: The present invention relates to a method for predicting clinical outcome for a subject diagnosed with colorectal cancer, skin cancer, head and neck cancer or lung cancer. It also relates to a method for predicting whether a subject has a predisposition to develop such cancers as well as to a method for aiding the staging of such cancers in a subject. The methods of the present invention apply to the biomarkers MYO5B and/or RAB8A and optionally in addition to RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC and/or RhoA.
    Type: Application
    Filed: August 10, 2018
    Publication date: November 19, 2020
    Inventors: Elisabeth Letellier, Martine Schmitz, Aurelien Ginholac, Serge Haan
  • Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro
    Publication number: 20110300113
    Abstract: The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.
    Type: Application
    Filed: September 19, 2007
    Publication date: December 8, 2011
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Ana Martin-Villalba, Nina Corsini, Elisabeth Letellier, Susanne Kleber, Stefan Klussmann
  • USE OF CD95 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20110189194
    Abstract: The present invention refers to the use of an inhibitor of the CD95/CD95L system for the prevention and/or treatment of an inflammatory disorder or for the prevention and/or treatment of an inflammatory process in a neuronal disorder, particularly in a CNS disorder.
    Type: Application
    Filed: July 14, 2009
    Publication date: August 4, 2011
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Ana Martin-Villalba, Elisabeth Letellier, Ignacio Sancho-Martinez